Analysts Set Expectations for BNTC Q2 Earnings

Benitec Biopharma Inc. (NASDAQ:BNTC) – Analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Benitec Biopharma in a research report issued on Monday, December 16th. HC Wainwright analyst R. Selvaraju forecasts that the biotechnology company will earn ($0.27) per share for the quarter. HC Wainwright has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($4.33) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.

A number of other research firms have also issued reports on BNTC. Oppenheimer began coverage on shares of Benitec Biopharma in a report on Wednesday, October 16th. They issued an “outperform” rating and a $35.00 target price on the stock. Baird R W raised shares of Benitec Biopharma to a “strong-buy” rating in a research note on Thursday, December 12th. Piper Sandler reaffirmed an “overweight” rating on shares of Benitec Biopharma in a research note on Friday, October 18th. JMP Securities increased their price target on Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a research note on Monday, October 14th. Finally, Guggenheim reiterated a “buy” rating and issued a $17.00 target price on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Benitec Biopharma presently has a consensus rating of “Buy” and an average target price of $24.43.

Benitec Biopharma Stock Up 2.8 %

Shares of NASDAQ:BNTC opened at $12.17 on Thursday. The company has a market capitalization of $282.54 million, a P/E ratio of -4.29 and a beta of 0.88. Benitec Biopharma has a 52-week low of $2.69 and a 52-week high of $13.29. The stock’s fifty day simple moving average is $10.77 and its 200-day simple moving average is $9.40.

Institutional Trading of Benitec Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC acquired a new position in shares of Benitec Biopharma during the second quarter worth about $5,881,000. Simplify Asset Management Inc. raised its holdings in shares of Benitec Biopharma by 127.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 116,535 shares of the biotechnology company’s stock valued at $1,071,000 after buying an additional 65,319 shares during the period. Suvretta Capital Management LLC raised its holdings in shares of Benitec Biopharma by 422.0% during the 3rd quarter. Suvretta Capital Management LLC now owns 8,829,053 shares of the biotechnology company’s stock valued at $81,139,000 after buying an additional 7,137,763 shares during the period. GAMMA Investing LLC lifted its position in Benitec Biopharma by 20.3% during the 3rd quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 1,102 shares in the last quarter. Finally, Acuta Capital Partners LLC purchased a new position in Benitec Biopharma in the 3rd quarter worth approximately $274,000. 52.19% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Benitec Biopharma

In other Benitec Biopharma news, Director Suvretta Capital Management, L acquired 42,000 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $9.60 per share, with a total value of $403,200.00. Following the completion of the transaction, the director now directly owns 7,957,365 shares of the company’s stock, valued at approximately $76,390,704. The trade was a 0.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.30% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.